OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter
(NASDAQ:OKYO), LONDON and NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dollar market, today announces a clinical update […]